Lisata Therapeutics Inc (LSTA) Stock Price, Quote & News

Company Profile

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with a range of anti-cancer regimen...

Industry: Biotechnology

Sector: Healthcare

Phone: 908 842 0100

Website: www.lisata.com

Address:

110 Allen Road, 2nd Floor, Basking Ridge, United States

ShieldedSphere Dec. 25 at 5:46 PM

$LSTA Investors are recalibrating expectations as the balance shifts from vision to execution. Sequential improvement must start appearing across core metrics. Momentum becomes sustainable only with dependable execution. The next phase will be defined less by vision and more by delivery.

0 · Reply

Slide3 Dec. 23 at 8:10 PM

$LSTA And now the rug pull......

0 · Reply

PyraWeb Dec. 23 at 3:35 PM

$LSTA 1D 12/23/2025 PyraWeb chamber level sine waves. 2.22 is a level derived via both the center and side set sine waves(Blue and orange lines). Being under 2.22 is crap…and the interview posted here recently…Mazzo shouldn’t be surprised no one is “trading” LSTA. It’s all long bags until he makes it something. It’s on LSTA to create the hype, not us. I can tell Mazzo wishes many would take the L so the parasites can swoop in and buy the blood, and move the stock,but instead they need to do their job and create value for their investors. They set the terms for the stock; I don’t like Mazzo being puzzled that his investors don’t want to take a big loss “trading”. Nothing to trade bro, it’s been a fcuking wipe out. Road to 1.69-1.57 levels has two sine wave support tests. But being under long term support 2.22 is just another failure of the stock. Another aspect is price nearing potential exit of PyraWeb structure which gives a lot of potential but also additional resistance checks.

1 · Reply

Slide3 Dec. 22 at 9:13 PM

$LSTA Seems like bids are a little stronger past couple of days. Is any good news on the horizon? I still think the best outcome here is Catalent presents more evidence that certepetide potentiates ADCs.

1 · Reply

Djdanny Dec. 16 at 4:18 PM

$LSTA $ORGO STRONG BUY ❤️The FDA confirmed that the ReNu clinical development program, which includes two large Phase 3 randomized controlled trials (RCT), a separate 200-patient study, and extensive commercial history, is appropriate for BLA submission. Organogenesis expects to initiate the rolling BLA before the end of December 2025.

0 · Reply

PyraWeb Dec. 15 at 6:26 PM

$LSTA 1D 12/15/2025 PyraWeb When price couldn’t hold around 2.66, I assume(d) the next horizontal will come 1.69. And without the company it likely gets there. At least they seem to finally care about PPS…but they haven’t cared for way too long….Now they need to figure how to not screw us anymore and get out of the rut. Based on what’s been coming out, this should go high, but they need to be creative here. Sick of excuses, get it done.

1 · Reply

cavsnut Dec. 14 at 9:54 PM

$LSTA 25:32 mark, hmmmm…. https://edge.media-server.com/mmc/p/d7yefkch/

1 · Reply

Djdanny Dec. 12 at 5:19 PM

$ACRV $LSTA My next winner

0 · Reply

Djdanny Dec. 12 at 5:18 PM

$LSTA My next winner

0 · Reply

EdwardTeach Nov. 21 at 2:48 PM

$LSTA partner or buyout, what will it be?....glta

1 · Reply

Lisata Therapeutics, Inc. (LSTA) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 4:05 PM EST - 7 weeks ago

Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 6, 2025, 8:00 AM EST - 7 weeks ago

Lisata Therapeutics Wins 2025 BioTech Breakthrough Award for ‘Overall BioPharma Solution of the Year'

Nov 4, 2025, 4:00 PM EST - 7 weeks ago

Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent

Oct 30, 2025, 8:00 AM EDT - 2 months ago

Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025

Oct 13, 2025, 8:00 AM EDT - 2 months ago

Lisata Therapeutics to Present at LD Micro Main Event XIX

Oct 8, 2025, 8:30 AM EDT - 2 months ago

Lisata Therapeutics and Catalent Announce Global Antibody-Drug Conjugate (ADC) License Agreement

Sep 29, 2025, 8:00 AM EDT - 3 months ago

Lisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX Trial

Sep 2, 2025, 8:00 AM EDT - 4 months ago

Lisata Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 8, 2025, 3:05 AM EDT - 4 months ago

Lisata Therapeutics, Inc. (LSTA) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:05 PM EDT - 5 months ago

Lisata Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 31, 2025, 8:00 AM EDT - 5 months ago

Lisata Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update on Thursday, August 7, 2025

Jul 17, 2025, 8:00 AM EDT - 5 months ago

Lisata Therapeutics and WARPNINE Announce iLSTA Trial Enrollment Completion and Provide Preliminary Data Update

Jul 15, 2025, 8:00 AM EDT - 5 months ago

Lisata Therapeutics Expands Intellectual Property Portfolio with New Composition of Matter Patent for Certepetide

Jun 17, 2025, 8:00 AM EDT - 6 months ago

Lisata Therapeutics and GATC Health Expand Relationship to Advance AI-Driven Drug Discovery and Development

Jun 11, 2025, 8:30 AM EDT - 7 months ago

Lisata Therapeutics to Present at the 2025 BIO International Convention

May 8, 2025, 9:57 PM EDT - 8 months ago

Lisata Therapeutics, Inc. (LSTA) Q1 2025 Earnings Conference Call Transcript

May 8, 2025, 4:05 PM EDT - 8 months ago

Lisata Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 1, 2025, 8:00 AM EDT - 8 months ago

Lisata Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update on Thursday, May 8, 2025

Apr 15, 2025, 8:00 AM EDT - 9 months ago

Lisata Therapeutics Announces Research License with Catalent

Mar 6, 2025, 8:30 AM EST - 10 months ago

Lisata Therapeutics to Present at the Investival Showcase USA

Mar 5, 2025, 8:30 AM EST - 10 months ago

Lisata Therapeutics and GATC Health Consummate First Step in Strategic Collaboration to use AI to Derisk and Accelerate Drug Development

Feb 27, 2025, 10:06 PM EST - 10 months ago

Lisata Therapeutics, Inc. (LSTA) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 4:05 PM EST - 10 months ago

Lisata Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Feb 20, 2025, 8:00 AM EST - 11 months ago

Lisata Therapeutics to Report Full Year 2024 Financial Results and Provide a Business Update on Thursday, February 27, 2025

Jan 15, 2025, 8:30 AM EST - 1 year ago

Lisata Therapeutics to Present at the 2025 Sequire Investor Summit

Dec 10, 2024, 8:30 AM EST - 1 year ago

Lisata Therapeutics Announces Completion of Enrollment in the CENDIFOX Trial

Nov 19, 2024, 8:30 AM EST - 1 year ago

Lisata Therapeutics Wins 2024 BioTech Breakthrough Award for ‘Specialized BioTherapeutics Company of the Year'

Nov 12, 2024, 10:07 PM EST - 1 year ago

Lisata Therapeutics, Inc. (LSTA) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 4:05 PM EST - 1 year ago

Lisata Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 6, 2024, 9:23 AM EST - 1 year ago

Lisata Therapeutics and Valo Therapeutics Announce Preclinical Research Collaboration

Nov 6, 2024, 8:30 AM EST - 1 year ago

Lisata Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update on Tuesday, November 12, 2024

Oct 31, 2024, 8:30 AM EDT - 1 year ago

Lisata Therapeutics to Participate in Upcoming November 2024 Industry and Investor Events

Oct 28, 2024, 8:30 AM EDT - 1 year ago

Lisata Therapeutics Announces Sponsored Preclinical Research Agreement with the University of Cincinnati to Study Certepetide for the Treatment of Endometriosis

Sep 9, 2024, 8:00 AM EDT - 1 year ago

Lisata Therapeutics to Participate in Upcoming September 2024 Industry and Investor Events

Sep 5, 2024, 8:00 AM EDT - 1 year ago

Lisata Therapeutics' Certepetide Granted FDA Orphan Drug Designation for the Treatment of Cholangiocarcinoma

Aug 13, 2024, 12:20 AM EDT - 1 year ago

Lisata Therapeutics, Inc. (LSTA) Q2 2024 Earnings Call Transcript

Jul 18, 2024, 8:00 AM EDT - 1 year ago

Haystack Oncology and Lisata Therapeutics Initiate Research Collaboration to Use the Haystack MRD™ Technology to Evaluate Efficacy of Pancreatic Cancer Therapy

Jul 16, 2024, 8:00 AM EDT - 1 year ago

Lisata Therapeutics Announces Completion of Enrollment in its Phase 2a BOLSTER Trial of Certepetide in First-Line Cholangiocarcinoma

Jul 10, 2024, 8:00 AM EDT - 1 year ago

Lisata Therapeutics' Certepetide Shows Promise in Improving Standard Treatment for Intrahepatic Cholangiocarcinoma in a Preclinical Model

Jun 13, 2024, 8:30 AM EDT - 1 year ago

Lisata Therapeutics Announces Full Enrollment of Pancreatic Cancer Cohort of CENDIFOX Trial

May 28, 2024, 8:30 AM EDT - 1 year ago

Lisata Therapeutics to Participate in Upcoming June 2024 Industry and Investor Events

May 20, 2024, 8:30 AM EDT - 1 year ago

Lisata Therapeutics Receives Paediatric Investigation Plan Waiver from the European Medicines Agency for Certepetide in Pancreatic Cancer

May 9, 2024, 9:42 PM EDT - 1 year ago

Lisata Therapeutics, Inc. (LSTA) Q1 2024 Earnings Call Transcript

May 9, 2024, 4:05 PM EDT - 1 year ago

Lisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

May 2, 2024, 8:00 AM EDT - 1 year ago

Lisata Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update on Thursday, May 9, 2024

Apr 23, 2024, 7:30 AM EDT - 1 year ago

Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu's Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Apr 9, 2024, 8:30 AM EDT - 1 year ago

Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma

Apr 3, 2024, 8:30 AM EDT - 1 year ago

Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events

Mar 21, 2024, 8:00 AM EDT - 1 year ago

Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma

ShieldedSphere Dec. 25 at 5:46 PM

0 · Reply

Slide3 Dec. 23 at 8:10 PM

$LSTA And now the rug pull......

0 · Reply

PyraWeb Dec. 23 at 3:35 PM

1 · Reply

Slide3 Dec. 22 at 9:13 PM

1 · Reply

Djdanny Dec. 16 at 4:18 PM

0 · Reply

PyraWeb Dec. 15 at 6:26 PM

1 · Reply

cavsnut Dec. 14 at 9:54 PM

$LSTA 25:32 mark, hmmmm…. https://edge.media-server.com/mmc/p/d7yefkch/

1 · Reply

Djdanny Dec. 12 at 5:19 PM

$ACRV $LSTA My next winner

0 · Reply

Djdanny Dec. 12 at 5:18 PM

$LSTA My next winner

0 · Reply

EdwardTeach Nov. 21 at 2:48 PM

$LSTA partner or buyout, what will it be?....glta

1 · Reply

PyraWeb Nov. 14 at 9:58 PM

$LSTA 11/14/2025 1D PyraWeb Price showing support at chamber and wall today, just such little volume. The shadow has filled as predicted, :p. It potentially filled the mid April gap today via a wick that, that I’ve long predicted will be filled too ;p. Just gotta see if it needs a candle to deem it filled… anyway, I believe it’s the lowest daily chart gap, so that’s good.

0 · Reply

MarieRose Nov. 10 at 1:16 PM

$GLTO $LSTA is sympathy here. It has a low float, good earnings, and cash until 2027.

0 · Reply

EdwardTeach Nov. 7 at 10:14 PM

$LSTA Every time good news comes in it sinks lower....glta

0 · Reply

dumbquestioner Nov. 7 at 4:00 AM

$LSTA Vanguard does not allow purchase of Lisata shares online - you must call to make a purchase. Do other brokers do the same for LSTA? Any idea why they have this policy? I thought the Q&A comments were most interesting. ASCEND Phase 3 will be expensive and cost is not in the cash runway. Company is unwilling to raise capital for Phase 3 at price it would take currently so they are doing agreements as they find them to move forward. Absent good results how will the shares rise? How can you get the good results without spending on Phases 3? Will the current development plan work?

5 · Reply

EdwardTeach Nov. 6 at 11:09 PM

$LSTA "Earnings call transcript: Lisata Therapeutics Q3 2025 beats EPS estimates, stock drops" https://www.investing.com/news/transcripts/earnings-call-transcript-lisata-therapeutics-q3-2025-beats-eps-estimates-stock-drops-93CH-4340684

0 · Reply

PyraWeb Nov. 6 at 10:27 PM

$LSTA PyraWeb, you could hear the frustration in Mazzo’s voice, and it has been a frustrating experience because it feels like now they are being punished for progress. Stifled. It just needs a spark to start the fire, once investors pile in this will move fast. Today while filling shadow, price found support on cap wall…but 2.66 and 3.00 are the key level areas that resisted. I continue to think this will break out soon, but this asset has been THE hardest to chart of any in all my days….thats what makes me think it’s gonna be massive. Patience.

1 · Reply

Slide3 Nov. 6 at 10:19 PM

$LSTA Mazzo must have read my message, he was more personable today.

0 · Reply

EdwardTeach Nov. 6 at 9:31 PM

$LSTA https://www.stocktitan.net/news/LSTA/lisata-therapeutics-reports-third-quarter-2025-financial-results-and-dfscrhyzunnz.html

0 · Reply

TwongStocks Nov. 6 at 9:20 PM

$LSTA New investor presentation updated today. They updated the final ASCEND data to Q1 2026. https://www.sec.gov/Archives/edgar/data/320017/000032001725000069/lstacorporatepresentatio.htm

0 · Reply

TwongStocks Nov. 6 at 9:09 PM

$LSTA Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update https://ir.lisata.com/news-releases/news-release-details/lisata-therapeutics-reports-third-quarter-2025-financial-results • Final data and key findings from both cohorts of the ASCEND study are anticipated for Q1 of next year. • Additional CENDIFOX data are expected in the coming months under the auspices of the investigator. • Qilu has completed enrollment in its Phase 2 trial and data are expected in 2026. • Final data from iLSTA trial are anticipated in Q1 of 2026. • As of September 30, 2025, cash of approximately $19.0 million. Company believes available funds will support current operations into the first quarter of 2027.

0 · Reply

Defen Nov. 6 at 4:04 PM

$LSTA earnings after close today

0 · Reply

EdwardTeach Nov. 6 at 2:38 PM

$LSTA https://finance.yahoo.com/news/lisata-therapeutics-wins-2025-biotech-130000148.html

1 · Reply

Market Cap	18.26M
Revenue (ttm)	1.00M
Net Income (ttm)	-19.99M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,999.00%
Debt to Equity Ratio	0.00

Volume	18,000
Avg Vol	73,398
Day's Range	N/A - N/A
Shares Out	8.82M
Stochastic %K	43%
Beta	1.09
Analysts	Strong Sell
Price Target	$12.00